CraniotomyNCT01923571
Blood Glucose Concentration & Craniotomy
An observational study of Craniotomy, run by University of Roma La Sapienza at 2 sites in Italy.
Trial summary
Intraoperative blood glucose concentration abnormalities are associated with increased perioperative morbidity and mortality (1-4). Severe intraoperative hyperglycemia (BGC ≥ 200 mg/dl) in patients undergoing craniotomy for urgent/emergent craniotomy after traumatic brain injury complicates 15% of the cases and is… Read more about this study
- Who is it for?
- Ages 18 to 85 years
- Conditions the study is for
- Craniotomy
- What is being tested?
- intraoperative BGC measure
- How many people
- 53 participants
- Where
- 2 sitesItaly
- Study dates
- Apr 2013to Jun 2014
- Phase
- Observational
- Are there results?
- None posted in the registry
Key requirements
Who can take part, as listed by the sponsor. Only the study team can confirm whether you are eligible, so take this list to your doctor.
- Ages 18 to 85 years
- All sexes
- No healthy volunteers
- Adult, Older adult
Study population: at least 28 patients in each group
Who may be able to join
- patients undergoing craniotomy
Who cannot join
- age <18 years
Trial locations and contacts
2 sites in 1 country.
Federico Bilotta, MD contact
Italy2 sites, 2 recruiting
- Recruiting
Policlinico Umberto I
Rome, 00161
Federico Bilotta, MD, PhD, 39 339 33 708 22
Federico Bilotta, MD, PhD
- Recruiting
Policlinico Umberto I, Rome, Italy
Rome
Federico Bilotta, MD, PhD, 39 3393370822
About this study
Official title: Blood Glucose Concentration During Craniotomy: Epidemiology and Relationship With Postoperative Infections
Intraoperative blood glucose concentration abnormalities are associated with increased perioperative morbidity and mortality (1-4). Severe intraoperative hyperglycemia (BGC ≥ 200 mg/dl) in patients undergoing craniotomy for urgent/emergent craniotomy after traumatic brain injury complicates 15% of the cases and is associated with higher in-hospital mortality. Intraoperative use of dexamethasone during craniotomy is also known to induce an increase in blood glucose concentration.
The importance of blood glucose concentration in neurosurgical patients is witnessed by the effects of tight blood glucose control on incidence of infections and neurological outcome . Currently available evidence suggest that, in neurosurgical patients, perioperative BGC values should be within the 80-180 mg/dl range .
Read more
Data on the prevalence of severe intraoperative hyper (blood glucose concentration >180 mg/dl) and hypoglycemia (blood glucose concentration <80 mg/dl) in patients undergoing craniotomy for supra or infratentorial surgery as elective or emergency procedure are lacking as it is not known whether in these patients intraoperative severe hyperglycemia relates to an increased incidence of postoperative infections is unknown.
Aim of this prospective observational study -in patients undergoing craniotomy for supra or infratentorial surgery as elective or emergency procedure- was to test the hypothesis that severe intraoperative hyperglycemia (blood glucose concentration ≥180mg/dl) is associated with an increased incidence of infections within the first postoperative week (pneumonia, sepsis, urinary and wound and cerebral infections). We also recorded the prevalence of severe intraoperative hyper and hypoglycemia (blood glucose concentration<80 mg/dl) in recruited patients.
Read the detailed description
METHODS Study Design This prospective observational cohort study, in adult patients who underwent craniotomy for supra or infratentorial surgery as elective or emergency procedure, was approved by the University of Rome "Sapienza", Policlinico Umberto I hospital, Institutional Review Board (2665, 28/3/2013). Recruited patients were categorized according the type of procedure into 4 groups: primary brain tumors (gliomas and meningiomas); metastatic tumors; neurovascular lesions (intracranial hemorrhage, subarachnoid hemorrhage, arterovenous malformation); traumatic brain injury (14-16). In each group "elective" and "emergency" procedures were recorded apart. Because of the observational study design, perioperative clinical management was run by the attending anesthesiologist. Standard of care guidelines do not include the use of insulin infusion should full nutritional supply is not provided.
Patients population Adults ≥18 years of age, who underwent elective or emergency craniotomy for brain lesions in the supra or infratentorial space were prospectively recruited. In all patients intraoperative blood glucose concentration was measured twice: at the beginning of the procedure (immediately after endotracheal intubation) and at the end of surgery (immediately before extubation) on arterial whole blood by blood gas analysis (Instrumentation Laboratory, BGA analyzer GEM 4000, UK). Patients with one or both BGC>180 mg/dl were categorized as having "severe intraoperative hyperglycemia".
Intraoperative Setting All patients received normal saline (NaCl 0.9%) as pre and intraoperative fluid infusion. There was no fixed protocol for the anesthetic management and the anesthetic regime was determined by the attending anesthesiologist. Anesthesia was maintained with either halogenated inhalational anaesthetics (desflurane or sevoflurane) or with continuous propofol infusion and fentanyl as per clinical needs. Intraoperative monitoring was accomplished with 3 leads ECG, SpO2, end tidal CO2, invasive arterial pressure, core body temperature and urine output. Patients were normoventilated (PaCO2 35-40 mmHg) and mild hyperventilation was used to facilitate brain relaxation only when necessary . There was no dedicated protocol for treatment of intraoperative hyperglycemia and intraoperative insulin use was discouraged unless the attending anesthesiologist considered it necessary. Recorded demographic and clinical characteristics included: age, gender, localization of the brain lesion (supra or infratentorial), type of surgery (primary brain tumors, metastatic brain tumors, neurovascular, traumatic brain), setting of surgery (elective or emergent), duration of surgery, history of diabetes mellitus (and the use of chronic oral hypoglycemic agents or insulin), associated cardiac, vascular, renal or hepatic morbidity the intraoperative use of mannitol and steroids. In the postoperative period, all patients were kept fasting for the first 24 hours, subsequently full calories load -by self alimentation or enteral/parenteral nutrition- was warranted. As per local protocol, in the postoperative period, insulin was administered only in patients with blood glucose concentration> 180 mg/dl.
Definitions Hyperglycemia was defined as BGC ≥ 180 mg/dL. Hypoglycemia was defined as glucose≤ 80 mg/dL. Postoperative infections (pneumonia, blood stream-sepsis, urinary, surgical site/wound and cerebral infections) diagnosed according to Center for Disease Control and Prevention criteria within 7 days after surgery . The onset and type of infection was determined by 2 consultants for infective disease.
Outcomes The primary outcome was the prevalence of postoperative infections in normoglycemic patients and in those that presented at one intraoperative blood glucose concentration ≥ 180 mg/dL.
Secondary outcomes measures were: incidence of severe intraoperative hyper (blood glucose concentration ≥180 mg/dL) and hypo (blood glucose concentration <80 mg/dL) glycemia in patients undergone craniotomy; the relationship between the setting of surgery (elective or emergency), history of diabetes mellitus and intraoperative use of mannitol or steroids and severe intraoperative hyperglycemia.
Statistical Analysis For sample size calculation, we hypothesize that incidence of post operative infections would be 30% higher in patients that had a severe intraoperative hyperglycemia. We estimated that 28 patients should be recruited in each study group to detect a 30% difference in the incidence of postoperative infections. A difference in the incidence of intraoperative hypo and hyper glycemia in the different subgroups of patients undergone craniotomy was calculated using the Chi square test.
- Conditions
- Craniotomy
- Being tested
- intraoperative BGC measure
What participants receive
What participants receive. In a randomised study each person is assigned to one group by chance.
intraoperative BGC measureOther
| Study group | Role | What they receive |
|---|---|---|
| Normoglycemia | patients with intraoperative BGC in the 80-180 mg/dl range Receives: Other: intraoperative BGC measure | |
| Hyperglycemia | patients with intraoperative BGC exceeding 180 mg/dl Receives: Other: intraoperative BGC measure |
What is being measured
The primary outcome is the main question the study is designed to answer.
Blood glucose control during craniotomy: epidemiology and relationship with postoperative infections
Measured: 7 postoperative days
Secondary outcomes (1)
Incidence of postoperative infections according the CDC criteria up to the 7th postoperative day
Measured: 7th postoperative day
Timeline
From the start of the study to its completion; the mark is today. Estimated dates are the sponsor’s plan.
- First posted15 Aug 2013 (estimated)
- Study startApr 2013
- Primary completionJun 2014
Resources
- Official record on ClinicalTrials.govThe registry entry this page is built from, with its full change history.
- Other trials for CraniotomyStudies of the same condition, open and under way.
- What the trial phases meanHow a treatment moves from first tests in people to approval.
More details
For doctors and researchers: how the study is designed, who runs it, and its registry IDs.
Study design
- Study type
- Observational
- Observational model
- Cohort
- Time perspective
- Prospective
- Enrolment
- 53 participants (estimated)
Sponsor and investigators
- Lead sponsor
- University of Roma La Sapienza
- Sponsor type
- University, hospital or other
- Responsible party
- Principal investigator, Federico Bilotta, University of Roma La Sapienza
IDs, dates and publications
- ClinicalTrials.gov ID
- NCT01923571
- Sponsor's protocol ID
- 2241985
- Status last verified
- Jun 2014
- First submitted
- 13 Aug 2013
- Last updated
- 25 Jun 2014
- Results posted
- No
- Data monitoring committee
- Yes
Study at a glance
From the registry record, last updated by the sponsor on 25 Jun 2014. Recruitment status is as the sponsor reported it: confirm with the study team.
- Official title
- Blood Glucose Concentration During Craniotomy: Epidemiology and Relationship With Postoperative Infections
- ClinicalTrials.gov ID
- NCT01923571
- Acronym / sponsor ID
- 2241985
- Conditions
- Craniotomy
- Study type
- Observational
- Recruitment status
- Unknown status
- Enrolment
- 53 participants (estimated)
- Lead sponsor
- University of Roma La SapienzaUniversity, hospital or other
- Study start
- Apr 2013
- Primary completion
- Jun 2014 (actual)
- First posted
- 15 Aug 2013 (estimated)
- Results
- Not posted in the source record
Clinical summary
The research question as the sponsor registered it. This describes what the study plans to test, not what it found.
Intraoperative blood glucose concentration abnormalities are associated with increased perioperative morbidity and mortality (1-4). Severe intraoperative hyperglycemia (BGC ≥ 200 mg/dl) in patients undergoing craniotomy for urgent/emergent craniotomy after traumatic brain injury complicates 15% of the cases and is associated with higher in-hospital mortality. Intraoperative use of dexamethasone during craniotomy is also known to induce an increase in blood glucose concentration.
The importance of blood glucose concentration in neurosurgical patients is witnessed by the effects of tight blood glucose control on incidence of infections and neurological outcome . Currently available evidence suggest that, in neurosurgical patients, perioperative BGC values should be within the 80-180 mg/dl range .
Data on the prevalence of severe intraoperative hyper (blood glucose concentration >180 mg/dl) and hypoglycemia (blood glucose concentration <80 mg/dl) in patients undergoing craniotomy for supra or infratentorial surgery as elective or emergency procedure are lacking as it is not known whether in these patients intraoperative severe hyperglycemia relates to an increased incidence of postoperative infections is unknown.
Aim of this prospective observational study -in patients undergoing craniotomy for supra or infratentorial surgery as elective or emergency procedure- was to test the hypothesis that severe intraoperative hyperglycemia (blood glucose concentration ≥180mg/dl) is associated with an increased incidence of infections within the first postoperative week (pneumonia, sepsis, urinary and wound and cerebral infections). We also recorded the prevalence of severe intraoperative hyper and hypoglycemia (blood glucose concentration<80 mg/dl) in recruited patients.
Detailed description
METHODS Study Design This prospective observational cohort study, in adult patients who underwent craniotomy for supra or infratentorial surgery as elective or emergency procedure, was approved by the University of Rome "Sapienza", Policlinico Umberto I hospital, Institutional Review Board (2665, 28/3/2013). Recruited patients were categorized according the type of procedure into 4 groups: primary brain tumors (gliomas and meningiomas); metastatic tumors; neurovascular lesions (intracranial hemorrhage, subarachnoid hemorrhage, arterovenous malformation); traumatic brain injury (14-16). In each group "elective" and "emergency" procedures were recorded apart. Because of the observational study design, perioperative clinical management was run by the attending anesthesiologist. Standard of care guidelines do not include the use of insulin infusion should full nutritional supply is not provided.
Patients population Adults ≥18 years of age, who underwent elective or emergency craniotomy for brain lesions in the supra or infratentorial space were prospectively recruited. In all patients intraoperative blood glucose concentration was measured twice: at the beginning of the procedure (immediately after endotracheal intubation) and at the end of surgery (immediately before extubation) on arterial whole blood by blood gas analysis (Instrumentation Laboratory, BGA analyzer GEM 4000, UK). Patients with one or both BGC>180 mg/dl were categorized as having "severe intraoperative hyperglycemia".
Intraoperative Setting All patients received normal saline (NaCl 0.9%) as pre and intraoperative fluid infusion. There was no fixed protocol for the anesthetic management and the anesthetic regime was determined by the attending anesthesiologist. Anesthesia was maintained with either halogenated inhalational anaesthetics (desflurane or sevoflurane) or with continuous propofol infusion and fentanyl as per clinical needs. Intraoperative monitoring was accomplished with 3 leads ECG, SpO2, end tidal CO2, invasive arterial pressure, core body temperature and urine output. Patients were normoventilated (PaCO2 35-40 mmHg) and mild hyperventilation was used to facilitate brain relaxation only when necessary . There was no dedicated protocol for treatment of intraoperative hyperglycemia and intraoperative insulin use was discouraged unless the attending anesthesiologist considered it necessary. Recorded demographic and clinical characteristics included: age, gender, localization of the brain lesion (supra or infratentorial), type of surgery (primary brain tumors, metastatic brain tumors, neurovascular, traumatic brain), setting of surgery (elective or emergent), duration of surgery, history of diabetes mellitus (and the use of chronic oral hypoglycemic agents or insulin), associated cardiac, vascular, renal or hepatic morbidity the intraoperative use of mannitol and steroids. In the postoperative period, all patients were kept fasting for the first 24 hours, subsequently full calories load -by self alimentation or enteral/parenteral nutrition- was warranted. As per local protocol, in the postoperative period, insulin was administered only in patients with blood glucose concentration> 180 mg/dl.
Definitions Hyperglycemia was defined as BGC ≥ 180 mg/dL. Hypoglycemia was defined as glucose≤ 80 mg/dL. Postoperative infections (pneumonia, blood stream-sepsis, urinary, surgical site/wound and cerebral infections) diagnosed according to Center for Disease Control and Prevention criteria within 7 days after surgery . The onset and type of infection was determined by 2 consultants for infective disease.
Outcomes The primary outcome was the prevalence of postoperative infections in normoglycemic patients and in those that presented at one intraoperative blood glucose concentration ≥ 180 mg/dL.
Secondary outcomes measures were: incidence of severe intraoperative hyper (blood glucose concentration ≥180 mg/dL) and hypo (blood glucose concentration <80 mg/dL) glycemia in patients undergone craniotomy; the relationship between the setting of surgery (elective or emergency), history of diabetes mellitus and intraoperative use of mannitol or steroids and severe intraoperative hyperglycemia.
Statistical Analysis For sample size calculation, we hypothesize that incidence of post operative infections would be 30% higher in patients that had a severe intraoperative hyperglycemia. We estimated that 28 patients should be recruited in each study group to detect a 30% difference in the incidence of postoperative infections. A difference in the incidence of intraoperative hypo and hyper glycemia in the different subgroups of patients undergone craniotomy was calculated using the Chi square test.
Study design
- Observational model
- Cohort
- Time perspective
- Prospective
- Number of arms
- 2
| Arm | Type | Receives |
|---|---|---|
| Normoglycemia | – | Other: intraoperative BGC measurepatients with intraoperative BGC in the 80-180 mg/dl range |
| Hyperglycemia | – | Other: intraoperative BGC measurepatients with intraoperative BGC exceeding 180 mg/dl |
Who may qualify
- Ages
- 18 to 85 years
- Sex
- All
- Healthy volunteers
- Not accepted
- Age groups
- Adult, Older adult
- Study population
- at least 28 patients in each group
Key inclusion criteria (1 listed)
- patients undergoing craniotomy
Key exclusion criteria (1 listed)
- age <18 years
Eligibility is decided by the study team after screening; this overview does not establish that a patient qualifies. Full inclusion and exclusion criteria.
Interventions
| Intervention | Type | Arms |
|---|---|---|
| intraoperative BGC measure | Other | Hyperglycemia, Normoglycemia |
Primary outcome
Blood glucose control during craniotomy: epidemiology and relationship with postoperative infections
Time frame: 7 postoperative days
1 secondary outcome
Incidence of postoperative infections according the CDC criteria up to the 7th postoperative day
Time frame: 7th postoperative day
Results and safety
Results are not available in the source record.
Research links
- Official record on ClinicalTrials.govLast updated by the sponsor 25 Jun 2014.
Related trials for Craniotomy
Recruiting
rTMS for Postoperative Brain Tumor Patients
Brain Tumors, Transcranial Magnetic Stimulation
Not yet recruiting
Sphenopalatine Ganglion Block Combined With Either Scalp Nerve Block or Local Wound Infiltration for Postoperative Analgesia in Adult Patients Undergoing Craniotomy: A Randomized Controlled Trial
Craniotomy Surgery
Active, not recruitingObservational study
Study on Prognosis of Acutely Ruptured Intracranial Aneurysms
Aneurysmal Subarachnoid Hemorrhage, Endovascular Procedures
Recruiting
Perioperative Multimodal Analgesia for Supratentorial Craniotomy
Postoperative Pain, Analgesia
Recruiting
A Study to Measure the Effect of Brain Stimulation on Hand Strength and Function in Patients With Brain Tumors
Brain Tumor, Brain Cancer
Referral and contact
AzTrials does not enrol participants or take referrals. Contact the study team or a site listed below; they decide who can take part. This study is not recruiting at the moment.
Federico Bilotta, MD contact
2 sites in 1 country: see every site and its status.
Questions about this trial
What is this clinical trial studying?
An observational study of Craniotomy, run by University of Roma La Sapienza at 2 sites in Italy.
The full registered description is in the About this study section and the official record.
Who may be eligible to take part?
The sponsor lists 1 inclusion and 1 exclusion criteria. Eligibility is decided by the study team after screening, so read the full criteria and contact a listed site.
Is this clinical trial currently recruiting?
The record says: status not confirmed, as of the sponsor's last update on 25 Jun 2014. Status can change between updates, so confirm with the study contact before making plans.
Where is the study taking place?
The record lists 2 sites in Italy. Whether a site is taking part right now should be confirmed with that site. See every site.
What are the possible benefits and risks?
They depend on the study and the treatment, and no study can promise a benefit. The study team explains the known risks during informed consent, before anyone joins; the record itself does not list them.
Are results available for this study?
Results are not available in the source record.
How can a doctor refer a patient or contact the research team?
Contact Federico Bilotta, MD (bilotta@tiscali.it), or a site near the patient. AzTrials does not enrol participants or take referrals.
What does the primary outcome measure?
Blood glucose control during craniotomy: epidemiology and relationship with postoperative infections (time frame: 7 postoperative days). It is what the study was designed to measure, not a finding.
Where can I read the original study information?
Does a listing mean the treatment is approved or proven to work?
No. A listing means the study is registered. It does not show that the treatment is safe, works, or is approved by a regulator.
How often is this information updated?
AzTrials copies changed records from ClinicalTrials.gov every night and reloads the whole registry every week. The sponsor last updated this record on 25 Jun 2014.